P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib

Direct CDKN2 modulation of CDK4 alters target engagement of CDK4 inhibitor drugs.

(2019) Jennifer L Green et al.   MOLECULAR CANCER THERAPEUTICS

Coordinated transcription of ANRIL and P16 genes is silenced by P16 DNA methylation

(2018) Ying Gan et al.   Chinese Journal of Cancer Research

FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

(2018) Anand Shah et al.   CLINICAL CANCER RESEARCH

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer

(2018) Silvia Paola Corona et al.   Drug Design Development and Therapy

MALAT1–miR663a negative feedback loop in colon cancer cell functions through direct miRNA–lncRNA binding

(2018) Wei Tian et al.   Cell Death & Disease

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

(2018) Jessica L.F. Teh et al.   CLINICAL CANCER RESEARCH

Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs

(2018) Robert Roskoski   PHARMACOLOGICAL RESEARCH

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

(2018) Francesco Schettini et al.   Frontiers in Oncology

Cell-Cycle Therapeutics Come of Age

(2017) Matthew Ingham et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

(2016) R. Finn et al.   ANNALS OF ONCOLOGY

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

(2016) J. R. Infante et al.   CLINICAL CANCER RESEARCH

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer

(2016) Ran Zhao et al.   EBioMedicine

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2015) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment

(2014) A. DeMichele et al.   CLINICAL CANCER RESEARCH

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

The p16-Specific Reactivation and Inhibition of Cell Migration Through Demethylation of CpG Islands by Engineered Transcription Factors

(2012) Baozhen Zhang et al.   HUMAN GENE THERAPY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells

(2012) L. Cen et al.   NEURO-ONCOLOGY

A 115-bp MethyLight assay for detection of p16 (CDKN2A) methylation as a diagnostic biomarker in human tissues

(2011) Jing Zhou et al.   BMC Medical Genetics

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

(2010) W. R. Wiedemeyer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA